ClinicalTrials.gg
CompletedNCT06086886Updated Mar 24, 2025

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

A Phase 1 interventional study of BMS-986454 and Placebo in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of BMS-986454 in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • Healthy Participants
  • BMS-986454
  • First-in-human
  • Safety
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are healthy as determined by the investigator based on review of medical history, physical examinations, 12-lead ECGs, and clinical laboratory tests obtained during the screening period.
  • Participant is willing and able to adhere to the study visit schedule and other protocol requirements.
  • A negative test for COVID-19, which will be performed in the manner mandated by the clinical site where this study is being conducted, at screening and admission.

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, 12-lead , or clinical laboratory tests beyond what is consistent with a healthy population in the region in which the study is conducted.
  • Participant was exposed to an drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
  • Inability to be venipunctured or tolerate venous access.

Note: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    BMS-986454

    Drug: BMS-986454

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugBMS-986454

    Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to approximately 4 months

  2. Number of participants with severe adverse events (SAEs)

    Time frame: Up to approximately 4 months

  3. Number of participants with physical examination abnormalities

    Time frame: Up to approximately 4 months

  4. Number of participants with vital sign abnormalities

    Time frame: Up to approximately 4 months

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to approximately 4 months

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 4 months

Secondary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: Up to approximately 3 months

  2. Time of maximum observed serum concentration (Tmax)

    Time frame: Up to approximately 3 months

  3. Area under concentration time curve from time 0 to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to approximately 3 months

  4. Incidence of anti-drug antibody (ADA) formation

    Time frame: Up to approximately 3 months

  5. Absolute Bioavailability (F) of BMS-986454

    Time frame: Up to approximately 3 months

07

Study locations

2 sites
  • Local Institution - 0002
    London, Greater London NW10 7EW, United Kingdom
  • Local Institution - 0001
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Oct 17, 2023
StartActual
Nov 16, 2023
Primary completionActual
Dec 20, 2024
CompletionActual
Dec 20, 2024
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06086886
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Nov 16, 2023
Primary completion
Dec 20, 2024
Completion
Dec 20, 2024
Last update
Mar 24, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion